Clinical trial
Observational Real-World Study on the Efficacy, Safety, and Biomarker Exploration of CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- Metastatic Breast Cancer.
NCT06033287 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Observational Real-World Study on the Efficacy, Safety, and Biomarker Exploration of CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- Metastatic Breast Cancer.
- Lead sponsor
- Hunan Cancer Hospital
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- January 1, 2023
- Completion date
- December 31, 2025
- Enrollment
- 300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, cdk4/6 inhibitors, endocrine therapy, subsequent treatment